The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The current role of MRD in CLL and future outlooks
Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, highlights the role of measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL), commenting on its potential use in defining duration of therapy and in the prognostication of patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
